Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: A network metaanalysis

Oncotarget

Volumn 7, Issue 50, 2016, Pages 82567-82579

  Zhuo, Chuanjun ^a,b,c   Li, Xubin ^d   Zhuang, Hongqing ^d   Tian, Shunli ^e   Cui, Hailong ^e   Jiang, Ronghuan ^f   Liu, Chuanxin ^b   Tao, Ran ^g   Lin, Xiaodong ^a  

^a Wenzhou Seventh People's Hospital   (China)

^b JINING MEDICAL UNIVERSITY   (China)

^c Tianjin Anding Hospital   (China)

^d KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^e TIANJIN MEDICAL UNIVERSITY   (China)

^f CHINESE PLA GENERAL HOSPITAL   (China)

^g Beijing Shijian Integrated Medicine Science Institute   (China)

Author keywords

Efficacy and safety; Intravesical therapy; Non muscle invasive bladder cancer; Tumor progression; Tumor recurrence

Indexed keywords

BCG VACCINE; EPIRUBICIN; GEMCITABINE; ISONIAZID; MITOMYCIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ARTICLE; CANCER CHEMOTHERAPY; CYSTITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEMATURIA; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; NON MUSCLE INVASIVE BLADDER CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR GROWTH; TUMOR RECURRENCE; AGED; ANALOGS AND DERIVATIVES; BAYES THEOREM; BLADDER TUMOR; DISEASE EXACERBATION; FEMALE; INTRAVESICAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; ODDS RATIO; PATHOLOGY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR INVASION; VERY ELDERLY;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; BCG VACCINE; DEOXYCYTIDINE; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 85003904921     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12856     Document Type: Article

References (54)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin. 2011; 61:69-90.
2. Hayne D, Stockler M, McCombie SP, Chalasani V, Long A, Martin A, Sengupta S, Davis ID. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301). BMC cancer. 2015; 15:432.
3. Saika T, Tsushima T, Nasu Y, Miyaji Y, Saegusa M, Takeda K, Kumon H. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study. World J Urol. 2010; 28:413-418.
4. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M. European Association of U. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64:639-653.
5. Chen SY, Du LD, Zhang YH. Pilot study of intravesical instillation of two new generation anthracycline antibiotics in prevention of superficial bladder cancer recurrence. Chin Med J (Engl). 2010; 123:3422-3426.
6. Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010; 28:543-548.
7. Braasch MR, Bohle A, O'Donnell MA. Risk-adapted use of intravesical immunotherapy. BJU Int. 2008; 102:1254-1264.
8. Bassi P. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol. 2002; 11:77-83.
9. Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and longterm results. Eur Urol. 2008; 53:45-52.
10. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with nonmuscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008; 53:709-719.
11. Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K, Yue ZJ, Tian JQ. Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2011; CD006885.
12. Malmstrom PU. Advances in intravesical therapy of urinary bladder cancer. Expert Rev Anticancer Ther. 2004; 4: 1057-1067.
13. Gontero P, Marini L, Frea B. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. BJU Int. 2005; 96:970-976.
14. Nagel S, Califano R, Thatcher N, Blackhall F. Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. Expert Opin Pharmacother. 2007; 8:3265-3275.
15. Doi K, Ohchi T, Ogata K, Matsuo A, Kudoh K, Ohtao R, Muranaka T. [Assessment of efficacy of arterial infusion chemotherapy with gemcitabine for four cases of advanced pancreatic cancer]. Gan to kagaku ryoho. 2007; 34: 2013-2015.
16. Gazzaniga P, Silvestri I, Gradilone A, Scarpa S, Morrone S, Gandini O, Gianni W, Frati L, Agliano AM. Gemcitabineinduced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. Anti-cancer drugs. 2007; 18:179-185.
17. Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Oncol. 2000; 53:676-680.
18. Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T, Fukatsu T, Ohno Y, Ohshima S, Nagoya University Urological Oncology G. Randomized study of single early instillation of (2"R)-4'-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer. 2002; 94:2363-2368.
19. Witjes JA. Topic issue on new treatments in bladder cancer. World J Urol. 2009; 27:285-287.
20. Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M, Martinez-Pineiro L, Rabadan M, Ojea A, Rodriguez-Molina J, et al. Sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate-and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol. 2015; 67:508-516.
21. Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, et al. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol. 2013; 190:857-862.
22. Järvinen R, Kaasinen E, Rintala E. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: A subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up. Scand J Urol Nephrol. 2012; 46:411-417.
23. Hinotsu S, Akaza H, Naito S, Ozono S, Sumiyoshi Y, Noguchi S, Yamaguchi A, Nagamori S, Terai A, Nasu Y, Kume H, Tomita Y, Tanaka Y, et al. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int. 2011; 108:187-195.
24. Oosterlinck W, Kirkali Z, Sylvester R, Silva FCD, Busch C, Algaba F, Collette S, Bono A. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with Bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: Results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol. 2011; 59:438-446.
25. Di Lorenzo G, Perdona S, Damiano R, Faiella A, Cantiello F, Pignata S, Ascierto P, Simeone E, De Sio M, Autorino R. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in nonmuscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010; 116:1893-1900.
26. Porena M, Del Zingaro M, Lazzeri M, Mearini L, Giannantoni A, Bini V, Costantini E. Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in highrisk superficial bladder cancer: a randomised prospective study. Urol Int. 2010; 84:23-27.
27. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM, Group EG-UTC. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010; 57:766-773.
28. Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S, Bartoletti R. Can Early Single Dose Instillation of Epirubicin Improve Bacillus Calmette-Guerin Efficacy in Patients With Nonmuscle Invasive High Risk Bladder Cancer? Results From a Prospective, Randomized, Double-Blind Controlled Study. J Urol. 2008; 180:110-115.
29. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence Rate Compared with Short-Term Intravesical Chemotherapy and Short-Term Therapy with Bacillus Calmette-Guérin (BCG) in Patients with Non-Muscle-Invasive Bladder Carcinoma. Eur Urol. 2007; 52:1123-1130.
30. Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JMF, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, et al. A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C. Eur Urol. 2007; 52:1398-1406.
31. Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Int J Urol. 2005; 12:449-455.
32. de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P, European Organization for the R, Treatment of Cancer-Genito-Urinary G. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906). J Urol. 2005; 173:405-409.
33. Kaasinen E, Wijkström H, Malmström PU, Hellsten S, Duchek M, Mestad O, Rintala E. Alternating mitomycin C, BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: A Nordic study. Eur Urol. 2003; 43:637-645.
34. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, Vespasiani G. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003; 170:777-782.
35. van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R, Members of the EG-UG. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol. 2001; 166:476-481.
36. Bilen CY, Özen H, Aki FT, Aygün C, Ekici S, Kendi S. Clinical experience with BCG alone versus BCG plus epirubicin. Int J Urol. 2000; 7:206-209.
37. Ali-El-Dein B, Nabeeh A, Ismail EH, Ghoneim MA. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: A randomized prospective study. J Urol. 1999; 162:339-342.
38. Witjes JA, Meijden APMVD, Collette L, Sylvester R, Debruyne FMJ, Van Aubel A, Witjes WPJ, Boeken K, Van A, Carpentier, De W, Oosterlinck, Bouffioux, et al. Long-term follow-up of an eortc randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. Urology. 1998; 52:403-410.
39. Melekos MD, Zarakovitis I, Dandinis K, Fokaefs E, Chionis H, Dauaher H, Barbalias G. BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes. Int Urol Nephrol. 1996; 28:499-509.
40. Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O, Hansson E, Juusela H, Kanerva K, Korhonen H, Permi J, Petäys P, Puolakka VM, Rajala P, et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol. 1996; 156:56-60.
41. Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith Jr JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, Barton Grossman H. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol. 1995; 1:119-126.
42. Hemdan T, Johansson R, Jahnson S, Hellstrom P, Tasdemir I, Malmstrom PU, Members of the Urothelial Cancer Group of the Nordic Association of U. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guerin with epirubicin and interferonalpha2b in patients with T1 bladder cancer. J Urol. 2014; 191:1244-1249.
43. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002; 168:1964-1970.
44. Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for nonmuscle-invasive bladder cancer. Eur Urol. 2009; 56:247-256.
45. Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M, Martinez-Pineiro L, Rabadan M, Ojea A, Rodriguez-Molina J, et al. Sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate-and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol. 2015; 67:508-516.
46. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009; 182: 2195-2203.
47. Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate-and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014; 65:69-76.
48. Higashihara E, Nutahara K, Kojima M, Okegawa T, Miura I, Miyata A, Kato M, Sugisaki H, Tomaru T. Significance of serum free prostate specific antigen in the screening of prostate cancer. J Urol. 1996; 156:1964-1968.
49. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004; 63:682-686; discussion 686-687.
50. Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986; 4:425-439.
51. Kaasinen E, Wijkstrom H, Malmstrom PU, Hellsten S, Duchek M, Mestad O, Rintala E, Nordic Urothelial Cancer G. Alternating mitomycin C, BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol. 2003; 43:637-645.
52. Oosterlinck W, Kirkali Z, Sylvester R, da Silva FC, Busch C, Algaba F, Collette S, Bono A. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol. 2011; 59:438-446.
53. Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe LM. The safety and efficacy of gemcitabine for the treatment of bladder cancer. Expert Rev Anticancer Ther. 2016; 16:255-271.
54. Ojea A, Nogueira JL, Solsona E, Flores N, Gomez JM, Molina JR, Chantada V, Camacho JE, Pineiro LM, Rodriguez RH, Isorna S, Blas M, Martinez-Pineiro JA, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol. 2007; 52:1398-1406.